CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 262 filers reported holding CLOVIS ONCOLOGY INC in Q3 2017. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $8,653,000 | +2803.7% | 1,802,756 | +3752.0% | 0.04% | +2000.0% |
| Q1 2020 | $298,000 | -98.0% | 46,800 | -92.0% | 0.00% | -97.0% |
| Q1 2019 | $14,577,000 | +540.2% | 587,318 | +363.2% | 0.07% | +500.0% |
| Q4 2018 | $2,277,000 | -39.9% | 126,800 | -1.7% | 0.01% | -31.2% |
| Q3 2018 | $3,789,000 | -49.5% | 129,000 | -21.8% | 0.02% | -46.7% |
| Q2 2018 | $7,503,000 | -87.7% | 165,000 | -85.7% | 0.03% | -88.2% |
| Q1 2018 | $61,033,000 | -21.5% | 1,155,937 | +1.0% | 0.26% | -24.1% |
| Q4 2017 | $77,792,000 | +2669.4% | 1,144,000 | +3713.3% | 0.34% | +2000.0% |
| Q2 2017 | $2,809,000 | -75.7% | 30,000 | -95.0% | 0.02% | -82.0% |
| Q1 2016 | $11,580,000 | +182.5% | 603,100 | +415.0% | 0.09% | +161.8% |
| Q4 2015 | $4,099,000 | -61.9% | 117,100 | 0.0% | 0.03% | -60.0% |
| Q3 2015 | $10,769,000 | +4.6% | 117,100 | 0.0% | 0.08% | +19.7% |
| Q2 2015 | $10,291,000 | +38.6% | 117,100 | +17.1% | 0.07% | +39.2% |
| Q1 2015 | $7,423,000 | – | 100,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Healthcare Value Capital, LLC | 250,000 | $1,200,000 | 4.04% |
| Palo Alto Investors LP | 4,469,411 | $21,453,000 | 1.12% |
| ARMISTICE CAPITAL, LLC | 2,256,000 | $10,829,000 | 0.37% |
| Vigilare Wealth Management | 32,200 | $155,000 | 0.15% |
| Ikarian Capital, LLC | 650,000 | $3,121,000 | 0.14% |
| Ikarian Capital, LLC | 642,108 | $3,082,000 | 0.14% |
| WELD CAPITAL MANAGEMENT LLC | 40,156 | $193,000 | 0.08% |
| PINNACLE ASSOCIATES LTD | 703,970 | $3,379,000 | 0.07% |
| Versant Venture Management, LLC | 101,855 | $489,000 | 0.05% |
| Kalos Management, Inc. | 23,750 | $114,000 | 0.05% |